摘要
目的研究细胞外基质金属蛋白酶诱导分子（CD147）在前列腺癌组织中的表达情况，探讨其临床意义。方法应用免疫组化SP法检测101例前列腺癌组织，90例前列腺增生组织，36例正常前列腺组织和15例胚胎前列腺组织中CD147的表达情况，并对CD147表达与前列腺癌临床病理指标的关系进行统计学分析。结果胚胎前列腺，正常前列腺，前列腺增生及前列腺癌组织CD147表达阳性率分别为：0，5．6％，23．3％，66．3％。前列腺癌与其他3组比较差异均统计学意义（均P〈0．01）。CD147蛋白的表达与肿瘤的TNM分期、包膜侵犯和WHO分级呈正相关。结论CD147检测有助于提高前列腺癌的早期诊断率，希望成为反映肿瘤恶性程度及预后判断的标记物。
Objective To investigate the expression of CD147 in prostate cancer and discuss its diagnostic value in prostate cancer. Methods The method of immunohistochemical SP was employed to detect the expression of CD147 in 101 cases of prostate cancer, 90 cases of benign prostatic hyperplasia, 36 cases of normal prostate and 15 cases of embryonic prostate by so as to evaluate its clinical significance in the histological classification and prognosis of prostate cancer. Results The CD147 expression was positively expressed in 67/101 （66. 3% ） of prostate cancer, 21/90 （23. 3% ） of benign prostatic hypertrophy, 2/36 （5. 6% ） of normal prostate and 0/15 （0. 0） of embryonic prostate respectively. A positive expression of CD147 was dramatically associated with TNM stage （ P 〈 0. 001 ）, the depth of prostatic capsule invasion （P =0. 002 ） and histological grade （P =0. 006）. Conclusions The detection of CD147 is helpful to raise the early diagnosis rate of prostate cancer. It will become a tumor marker of reflecting the malignant degree and predicting the prognosis of prostate cancer.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2009年第26期1844-1846,共3页
National Medical Journal of China
基金
国家高技术研究发展计划重大项目基金（2006AA02A245）
广东省自然科学基金（200323-E4053）
